Skip to main content

You may soon be able to shell out for snail-based pain medicine

snail venom pain relief 3 conus regius
Image used with permission by copyright holder
When it comes to treating chronic pain, your first thought may not be that the answer could reside in the venom of a tiny, red-shelled marine snail that feeds on a specific type of marine “fireworm.”

That’s possibly where you should have been looking, however, based on a new article published in the journal Proceedings of the National Academy of Sciences.

Recommended Videos

The paper describes a compound which blocks pain, discovered by scientists at the University of Utah, with support from researchers at the University of Florence, Kirksville College of Osteopathic Medicine, A. T. Still University, University of Mississippi Medical Center, and biotech company Kineta.

Please enable Javascript to view this content

Not only was the impact of the compound long-lasting, with its effects continuing for 72 hours after being injected into rodents, but it was also free of highly-addictive opioids, which kill 91 Americans every single day from drug overdoses.

The compound is derived from petide, a chemical component found in the venom of the particular snail in question, which uses it both to help immobilize prey and also as a defense mechanism.

“There are hundreds of species of snail, which hunt a wide variety of prey, such as fish, worms, and other snails,” Dr. J. Michael McIntosh, a professor of psychiatry and biology at the University of Utah, told Digital Trends. “They each have a unique cocktail of 200 or so components in their venom. Once we find a particular compound of interest, we can then begin surveying the other species of snails to see if we can find improved versions of that compound. As we did our tests, we found petide in the venom of the conus regis snail.”

The original petide worked well in rodent tests, although the team made further synthetic modifications to the compound based on differences in the receptors of humans. Now, they’re working to develop the compounds for clinical trials in humans. “It’s in pre-clinical stages at the moment,” McIntosh said. “We hope to advance that over the next year or two, so as to do drug testing in humans.”

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Rivian tops owner satisfaction survey, ahead of BMW and Tesla
The front three-quarter view of a 2022 Rivian against a rocky backdrop.

Can the same vehicle brand sit both at the bottom of owner ratings in terms of reliability and at the top in terms of overall owner satisfaction? When that brand is Rivian, the answer is a resonant yes.

Rivian ranked number one in satisfaction for the second year in a row, with owners especially giving their R1S and R1T electric vehicle (EV) high marks in terms of comfort, speed, drivability, and ease of use, according to the latest Consumer Reports (CR) owner satisfaction survey.

Read more
Hybrid vehicle sales reach U.S. record, but EV sales drop in third quarter
Tesla Cybertruck

The share of electric and hybrid vehicle sales continued to grow in the U.S. in the third quarter, the Energy Information Administration (EIA) reported this month.

Taken together, sales of purely electric vehicles (EVs), hybrids, and plug-in hybrids (PHEVs) represented 19.6% of total light-duty vehicle (LDV) sales last quarter, up from 19.1% in the second quarter.

Read more
Tesla’s ‘Model Q’ to arrive in 2025 at a price under $30K, Deutsche Bank says
teslas model q to arrive in 2025 at a price under 30k deutsche bank says y range desktop lhd v2

Only a short month and half ago, Tesla CEO Elon Musk told investors that outside of the just-released driverless robotaxi, a regular Tesla model priced at $25,000 would be “pointless” and “silly”.

"It would be completely at odds with what we believe,” Musk said.

Read more